Leo Lens Pharma

MediPrint Ophthalmics, formerly Leo Lens Pharma, is a private clinical-stage eye care pharmaceutical company based in San Diego developing drug-eluting contact lenses for sustained ocular drug delivery. Its core technology, the proprietary MediPrint digital printing process, applies ophthalmic drugs onto contact lenses to provide preservative-free, non-invasive, continuous dosing while also enabling vision correction. The company's lead program, LL-BMT1, is a weekly medicated contact lens that releases bimatoprost for the treatment of primary open-angle glaucoma and ocular hypertension. Beyond glaucoma, the company has described pipeline expansion efforts in dry eye, ocular allergy, myopia management, and post-cataract applications. The business is positioned at the intersection of ophthalmic pharma, drug delivery, and contact lens-based medical devices.